4.2 Article

Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Journal

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 26, Issue 3, Pages S39

Publisher

Elsevier BV
DOI: 10.1016/j.bbmt.2019.12.105

Keywords

-

Categories

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available